CytoMed Therapeutics (GDTC) announced that it has entered into a Memorandum of Understanding, MoU, with Universiti Malaya Medical Centre, UMMC, a teaching hospital under Universiti Malaya to establish a multi-site, first-in-human Phase I clinical trial to investigate the safety and efficacy of CytoMed’s patented allogeneic unmodified Gamma Delta T cells, CTM-GDT, for no-option cancer patients in Malaysia.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDTC:
- CytoMed completes acquisition of T cell technology of TC BioPharm
- CytoMed Therapeutics Finalizes Acquisition of T Cell Technology for Cancer Treatment in China and India
- Cytomed Therapeutics secures investment for subsidiary LongevityBank
- CytoMed Therapeutics Secures Investment and Advances China Strategy
- CytoMed Therapeutics’ ANGELICA Trial: A New Frontier in Cancer Treatment